BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024; and The proposal for issuance of Sweat Equity Shares pursuant to applicable provisions of the Companies Act, 2013, the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and other applicable laws and regulations to Key Managerial Personnel and/or Senior Management Personnel and/or Employee(s) of the Company including determination of the issue price if any, subject to such regulatory and statutory approvals as may be required including approval of the shareholders of the Company.